Future Science GroupBrowse
Supplementary Figure 1.jpg (823.7 kB)
Download file

Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients - Supplementary Figure 1

Download (823.7 kB)
figure
posted on 06.01.2022, 10:53 by Jianbo Zhu, Guangpeng Chen, Kai Niu, Yongdong Feng, Lijiao Xie, Si Qin, Zhongyu Wang, Jixi Li, Song Lang, Wenlei Zhuo, Zhengtang Chen, Jianguo Sun

Supplementary Figure 1. Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients

The outcomes of radiation pneumonitis (RP) in the Endostar group and the control group. The incidences of the RP remission, RP relapse and RP death were calculated based on the people who developed RP grade 2 and higher. The incidences of the pulmonary fibrosis were calculated based on the people who developed RP.

Funding

This study was supported by the National Key Research & Development Program (No. 2016YFC0106400), the National Natural Science Foundation of China (81773245, 81972858), the Technology Innovation and Application Development Project of Chongqing (cstccxljrc201910), and the Cultivation Program for Clinical Research Talents of Army Medical University (2018XLC1010).

History

Usage metrics

Read the peer-reviewed publication

Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients
Future OncologyFuture Oncology

Categories

Keywords

Recombinant human endostatin (Rh-endostatin)Non-small cell lung cancer (NSCLC)RadiotherapyPeri-radiotherapy periodRadiation TherapySolid TumoursCancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0

Exports